A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Trial Profile

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms IMvigor 130; IMvigor130
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 02 Feb 2017 Planned number of patients changed from 435 to 1200.
    • 02 Feb 2017 Atezolizumab will also be administered and studied as monotherapy hence treatment arm of Atezolizumab monotherapy added, planned patient number changed from 435 to 1200.
    • 02 Feb 2017 Planned End Date changed from 1 Jun 2020 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top